Source-grounded facts extracted from Zai Lab Ltd's SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Josh Smiley departed as President and Chief Operating Officer at Zai Lab Ltd.
“On May 18, 2026, the Board of Directors of Zai Lab Limited (the “Company”) determined that Mr. Josh Smiley will cease serving as President and Chief Operating Officer of the Company, effective as of May 18, 2026, and his last day of employment with the Company will be May 22, 2026.”
Zai Lab Ltd reported the first quarter of 2026 results: revenue $99.6 million, net income Net loss was $51.0 million, EPS loss per ADS of $0.46.
“forth by specific reference in such filing. --- EX-99.1 (EX-99.1) --- Zai Lab Announces First Quarter 2026 Financial Results and Recent Corporate Updates – Total revenues of $99.6 million for the first quarter of 2026, reflecting anticipated first-quarter dynamics, including certain competitive impacts for ZEJULA and pricing adjustment related to NRDL renewal for”
Harald Reinhart retired as President, Head of Global Development, Neuroscience, Autoimmune and Infectious Diseases at Zai Lab Ltd.
“On June 11, 2024 , Zai Lab Limited (the “Company”) announced that Dr. Harald Reinhart, President, Head of Global Development, Neuroscience, Autoimmune and Infectious Diseases, has informed the Company that he has decided to retire, effective June 30, 2024.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.